Umeå universitets logga

umu.sePublikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
Publikationer (10 of 16) Visa alla publikationer
Rosendal, E., Kalucza, S., Nyström, H., Schien, M., Berggren, R. K., Jerndal, H., . . . Fors Connolly, A.-M. (2025). External review of procedure codes for intensive care, mechanical ventilation and extracorporeal membrane oxygenation for critically ill COVID-19 patients in the Swedish inpatient register: a nationwide observational cohort study. European Journal of Anaesthesiology and Intensive Care, 4(2), Article ID e0071.
Öppna denna publikation i ny flik eller fönster >>External review of procedure codes for intensive care, mechanical ventilation and extracorporeal membrane oxygenation for critically ill COVID-19 patients in the Swedish inpatient register: a nationwide observational cohort study
Visa övriga...
2025 (Engelska)Ingår i: European Journal of Anaesthesiology and Intensive Care, E-ISSN 2767-7206, Vol. 4, nr 2, artikel-id e0071Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: The quality of registry data is important for epidemiological research. The Swedish inpatient registry (IPR) is a national database with mandatory registration of all hospitalisations since 1987, and since 2007, the medical procedure codes which can be used for grading severity of infectious diseases. However, the completeness of procedure code registration has rarely been studied.

OBJECTIVES: To determine the quality and completeness of procedure codes for ICU admission, mechanical ventilation and extra-corporeal membrane oxygenation (ECMO) in the Swedish IPR utilising the Swedish Intensive Care Registry (SIR) as the gold standard. DESIGN A Swedish nationwide observational study.

SETTING: Covid-19 patients in Sweden who required intensive care in Sweden between March 2020 and August 2022. PATIENTS Covid-19 patients with a laboratory-verified SARS-CoV-2 infection who required ICU admission (n=8992), mechanical ventilation (n=5262) or ECMO (n=29).

MAIN OUTCOME MEASURES: The sensitivity and/or positive predictive values of procedure code registration for ICU, mechanical ventilation, ECMO and Covid-19 diagnosis code registration in the IPR were evaluated using SIR as the reference. Factors associated with low reporting were explored and the dates of ICU admission registration compared between IPR and SIR.

RESULTS: For Covid-19 patients registered in SIR as needing intensive care, mechanical ventilation or ECMO, the completeness of procedure codes in the IPR was 39.7, 78.2 and 100%, respectively. Of the 39.7% with an ICU code in the IPR, the ICU date in the IPR corresponding to the actual ICU admission date was 52.3%. The completeness of ICU registration in the IPR varied from 0.6 to 96.9% between healthcare regions

CONCLUSIONS: Procedure codes for intensive care in the Swedish IPR showed low sensitivity and varied greatly between healthcare regions. This negatively influences their usability for epidemiological research and calls for updated guidelines on coding.

Ort, förlag, år, upplaga, sidor
Wolters Kluwer, 2025
Nationell ämneskategori
Anestesi och intensivvård Infektionsmedicin
Identifikatorer
urn:nbn:se:umu:diva-238453 (URN)10.1097/EA9.0000000000000071 (DOI)40206340 (PubMedID)2-s2.0-105001870869 (Scopus ID)
Forskningsfinansiär
Region Västerbotten, RV-982300Region Västerbotten, RV-996166Region Västerbotten, RV-967545Vetenskapsrådet, 2021–06536Kempestiftelserna, SMK21–0014Hjärt-Lungfonden, 20220179
Tillgänglig från: 2025-05-06 Skapad: 2025-05-06 Senast uppdaterad: 2025-05-06Bibliografiskt granskad
Hellman, U., Rosendal, E., Lehrstrand, J., Henriksson, J., Björsell, T., Wennemo, A., . . . Lenman, A. (2024). SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study. mBio, 15(10), Article ID e01303-24.
Öppna denna publikation i ny flik eller fönster >>SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study
Visa övriga...
2024 (Engelska)Ingår i: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 15, nr 10, artikel-id e01303-24Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1–5) and severe COVID-19 (WHO-CPS, 6–9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity. In vitro 3D-lung models, differentiated from primary human bronchial epithelial cells, were used to study the effects of SARS-CoV-2 infection on HA metabolism, and transcriptomic analyses revealed a dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Furthermore, corticosteroid treatment reduced the inflammation and downregulated HA synthases. Our findings demonstrate that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment.

Ort, förlag, år, upplaga, sidor
American Society for Microbiology, 2024
Nyckelord
COVID-19, hyaluronan, hyaluronic acid, SARS-CoV-2, lung impairment, 3D-lung model
Nationell ämneskategori
Infektionsmedicin
Identifikatorer
urn:nbn:se:umu:diva-229944 (URN)10.1128/mbio.01303-24 (DOI)001318493400001 ()39302125 (PubMedID)2-s2.0-85206959059 (Scopus ID)
Forskningsfinansiär
Hjärt-Lungfonden, 20200385Hjärt-Lungfonden, 20200325Hjärt-Lungfonden, 20210078Hjärt-Lungfonden, 20200366Hjärt-Lungfonden, 20210049Kempestiftelserna, JCK-1827Umeå universitet, 978018Umeå universitet, 964781Nyckelfonden, OLL-938628Nyckelfonden, OLL-961416Sjukvårdsregionala forskningsrådet Mellansverige, RFR-968856Sjukvårdsregionala forskningsrådet Mellansverige, RFR-940474Vetenskapsrådet, 2020-06235Vetenskapsrådet, 2016-06514Vetenskapsrådet, 2021-06602Åke Wibergs Stiftelse, M22-0106Magnus Bergvalls Stiftelse, 2022-186
Tillgänglig från: 2024-09-23 Skapad: 2024-09-23 Senast uppdaterad: 2024-10-28Bibliografiskt granskad
Rosendal, E., Lindquist, R., Chotiwan, N., Henriksson, J. & Överby, A. K. (2024). Transcriptional response to tick-borne flavivirus infection in neurons, astrocytes and microglia in vivo and in vitro. Viruses, 16(8), Article ID 1327.
Öppna denna publikation i ny flik eller fönster >>Transcriptional response to tick-borne flavivirus infection in neurons, astrocytes and microglia in vivo and in vitro
Visa övriga...
2024 (Engelska)Ingår i: Viruses, E-ISSN 1999-4915, Vol. 16, nr 8, artikel-id 1327Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Tick-borne encephalitis virus (TBEV) is a neurotropic member of the genus Orthoflavivirus (former Flavivirus) and is of significant health concern in Europe and Asia. TBEV pathogenesis may occur directly via virus-induced damage to neurons or through immunopathology due to excessive inflammation. While primary cells isolated from the host can be used to study the immune response to TBEV, it is still unclear how well these reflect the immune response elicited in vivo. Here, we compared the transcriptional response to TBEV and the less pathogenic tick-borne flavivirus, Langat virus (LGTV), in primary monocultures of neurons, astrocytes and microglia in vitro, with the transcriptional response in vivo captured by single-nuclei RNA sequencing (snRNA-seq) of a whole mouse cortex. We detected similar transcriptional changes induced by both LGTV and TBEV infection in vitro, with the lower response to LGTV likely resulting from slower viral kinetics. Gene set enrichment analysis showed a stronger transcriptional response in vivo than in vitro for astrocytes and microglia, with a limited overlap mainly dominated by interferon signaling. Together, this adds to our understanding of neurotropic flavivirus pathogenesis and the strengths and limitations of available model systems.

Ort, förlag, år, upplaga, sidor
MDPI, 2024
Nyckelord
interferon signaling, Langat virus, neuroinflammation, RNA sequencing, snRNA-seq, tick-borne encephalitis virus
Nationell ämneskategori
Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) Mikrobiologi inom det medicinska området
Identifikatorer
urn:nbn:se:umu:diva-229306 (URN)10.3390/v16081327 (DOI)001304785500001 ()39205301 (PubMedID)2-s2.0-85202478166 (Scopus ID)
Forskningsfinansiär
Vetenskapsrådet, 2018-05851Vetenskapsrådet, 2020-06224Kempestiftelserna, SMK-1654Kempestiftelserna, JCK-1827Umeå universitetCancerfondenKnut och Alice Wallenbergs Stiftelse, KAW2015.0284
Tillgänglig från: 2024-09-13 Skapad: 2024-09-13 Senast uppdaterad: 2025-03-03Bibliografiskt granskad
Wigren, J., Vikström, L., Rosendal, E., Gröning, R., Gwon, Y.-D., Nilsson, E., . . . Forsell, M. N. E. (2023). At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. Eurosurveillance, 28(13), Article ID 2200432.
Öppna denna publikation i ny flik eller fönster >>At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study
Visa övriga...
2023 (Engelska)Ingår i: Eurosurveillance, ISSN 1025-496X, E-ISSN 1560-7917, Vol. 28, nr 13, artikel-id 2200432Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: The current SARS-CoV-2 pandemic has highlighted a need for easy and safe blood sampling in combination with accurate serological methodology. Venipuncture for testing is usually performed by trained staff at healthcare centres. Long travel distances to healthcare centres in rural regions may introduce a bias of testing towards relatively large communities with closer access. Rural regions are therefore often not represented in population-based data.

Aim: The aim of this retrospective cohort study was to develop and implement a strategy for at-home testing in a rural region of Sweden during spring 2021, and to evaluate its role to provide equal health care for its inhabitants.

Methods: We developed a sensitive method to measure antibodies to the S-protein of SARS-CoV-2 and optimised this assay for clinical use together with a strategy of at-home capillary blood sampling.

Results: We demonstrated that our ELISA gave comparable results after analysis of capillary blood or serum from SARS-CoV-2-experienced individuals. We demonstrated stability of the assay under conditions that reflected temperature and humidity during winter or summer. By assessment of capillary blood samples from 4,122 individuals, we could show both feasibility of the strategy and that implementation shifted the geographical spread of testing in favour of rural areas.

Conclusion: Implementation of at-home sampling enabled citizens living in remote rural areas access to centralised and sensitive laboratory antibody tests. The strategy for testing used here could therefore enable disease control authorities to get rapid access to information concerning immunity to infectious diseases, even across vast geographical distance.

Ort, förlag, år, upplaga, sidor
European Centre for Disease Control and Prevention (ECDC), 2023
Nyckelord
coronavirus disease (COVID-19), laboratory, surveillance, Sweden
Nationell ämneskategori
Infektionsmedicin Mikrobiologi inom det medicinska området
Identifikatorer
urn:nbn:se:umu:diva-206673 (URN)10.2807/1560-7917.ES.2023.28.13.2200432 (DOI)000971868200003 ()36995373 (PubMedID)2-s2.0-85151573640 (Scopus ID)
Tillgänglig från: 2023-04-14 Skapad: 2023-04-14 Senast uppdaterad: 2023-09-05Bibliografiskt granskad
Rosendal, E. (2023). Host-pathogen interactions during tick-borne flavivirus infection: pathogenesis, tropism and tools. (Doctoral dissertation). Umeå: Umeå universitet
Öppna denna publikation i ny flik eller fönster >>Host-pathogen interactions during tick-borne flavivirus infection: pathogenesis, tropism and tools
2023 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Alternativ titel[sv]
Värd-patogen-interaktioner vid fästingburen flavivirus infektion : patogenes, tropism och verktyg
Abstract [en]

Tick-borne encephalitis virus (TBEV) is a neurotropic member of the genus Flavivirus. It may transmit to humans through the bite of an infected tick or consumption of unpasteurized dairyproducts, and causes tick-borne encephalitis (TBE). TBE constitutes a significant health burden in Eurasia, with more than 10,000 cases reported every year. In this thesis, I have investigated the role of the innate immune response in restricting infection in the central nervous system (CNS), identified virulence factors and developed a new model system to study the structural proteins of TBEV.

Viral tropism is important for understanding underlying mechanisms of pathology. In the first part,we combined whole-brain imaging with single nuclei RNA-sequencing after infection of wildtype (WT) and interferon (IFN) α/β receptor knockout (Ifnar-/-) mice by Langat virus (LGTV), a low-virulent model for TBEV. We found that absence of type I IFN signaling changes viral tropism and leads to an impaired inflammatory response. For neurons, astrocytes, and microglia we also compared the response to LGTV infection in vivo with the response of primary monocultures infected in vitro. Primary cells are often used for mechanistic studies of neurotropic viruses, but we found limited overlap in altered pathways between in vivo and in vitro, which emphasizes the role of cellular crosstalk in shaping the transcriptional response to infection in the brain.

The second part addresses viral determinants of pathogenicity. By comparing disease progression induced by different TBEV strains in a mouse model, we identified TBEV 93/783 as a highly virulentstrain belonging to the European subtype. We could show that two unusual amino acid substitutions in the envelope (E) protein of 93/783 enhanced neurovirulence and contributed to pathogenesis. To facilitate further studies of the structural proteins of TBEV, we generated and thoroughlycharacterized a chimeric virus with the pre-membrane (prM) and ecto-E protein of TBEV 93/783 in the genetic background of LGTV. The chimeric virus shows similar growth kinetics as the parental LGTV in vitro but is less pathogenic in our mouse model. Meanwhile, it remained neurovirulent and structurally similar to TBEV, making it a useful tool for studying the structural proteins of TBEV under lower biosafety conditions. Taken together, these findings deepen our understanding of what determines the outcome of tick-borne flavivirus infection and the utility of the available model systems for studying disease mechanisms. 

Ort, förlag, år, upplaga, sidor
Umeå: Umeå universitet, 2023. s. 61
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2244
Nyckelord
Tick-borne encephalitis virus, Langat virus, pathogenesis, type I interferons, central nervous system, neuroinflammation, structural proteins
Nationell ämneskategori
Mikrobiologi inom det medicinska området Infektionsmedicin
Forskningsämne
infektionssjukdomar; mikrobiologi
Identifikatorer
urn:nbn:se:umu:diva-207013 (URN)978-91-8070-072-6 (ISBN)978-91-8070-071-9 (ISBN)
Disputation
2023-05-26, Sal B, 9 tr., Tandläkarhögskolan, Norrlands universitetssjukhus, Umeå, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2023-04-28 Skapad: 2023-04-25 Senast uppdaterad: 2023-04-26Bibliografiskt granskad
Chotiwan, N., Rosendal, E., Willekens, S. M. A., Schexnaydre, E., Nilsson, E., Lindquist, R., . . . Överby, A. K. (2023). Type I interferon shapes brain distribution and tropism of tick-borne flavivirus. Nature Communications, 14(1), Article ID 2007.
Öppna denna publikation i ny flik eller fönster >>Type I interferon shapes brain distribution and tropism of tick-borne flavivirus
Visa övriga...
2023 (Engelska)Ingår i: Nature Communications, E-ISSN 2041-1723, Vol. 14, nr 1, artikel-id 2007Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Viral tropism within the brain and the role(s) of vertebrate immune response to neurotropic flaviviruses infection is largely understudied. We combine multimodal imaging (cm-nm scale) with single nuclei RNA-sequencing to study Langat virus in wildtype and interferon alpha/beta receptor knockout (Ifnar-/-) mice to visualize viral pathogenesis and define molecular mechanisms. Whole brain viral infection is imaged by Optical Projection Tomography coregistered to ex vivo MRI. Infection is limited to grey matter of sensory systems in wildtype mice, but extends into white matter, meninges and choroid plexus in Ifnar-/- mice. Cells in wildtype display strong type I and II IFN responses, likely due to Ifnb expressing astrocytes, infiltration of macrophages and Ifng-expressing CD8+ NK cells, whereas in Ifnar-/-, the absence of this response contributes to a shift in cellular tropism towards non-activated resident microglia. Multimodal imaging-transcriptomics exemplifies a powerful way to characterize mechanisms of viral pathogenesis and tropism.

Ort, förlag, år, upplaga, sidor
Springer Nature, 2023
Nationell ämneskategori
Mikrobiologi inom det medicinska området Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) Neurovetenskaper
Identifikatorer
urn:nbn:se:umu:diva-206780 (URN)10.1038/s41467-023-37698-0 (DOI)000967732600009 ()37037810 (PubMedID)2-s2.0-85152115180 (Scopus ID)
Forskningsfinansiär
Kempestiftelserna, SMK-1532Knut och Alice Wallenbergs Stiftelse, KAW2015.0284Vetenskapsrådet, 2018-05851Vetenskapsrådet, 2017-01307Vetenskapsrådet, 2020-06224Vetenskapsrådet, 2021-06602
Tillgänglig från: 2023-04-24 Skapad: 2023-04-24 Senast uppdaterad: 2025-03-03Bibliografiskt granskad
Welén, K., Rosendal, E., Gisslén, M., Lenman, A., Freyhult, E., Fonseca Rodriguez, O., . . . Josefsson, A. (2022). A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. European Urology, 81(3), 285-293
Öppna denna publikation i ny flik eller fönster >>A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
Visa övriga...
2022 (Engelska)Ingår i: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 81, nr 3, s. 285-293Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response.

Objective: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on SARS-CoV-2 infection.

Designs, settings, and participants: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2–positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells.

Intervention: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care.

Outcome measurements: The primary outcomes in COVIDENZA were the time to mechanical ventilation or discharge from hospital. The population-based study investigated risk of hospitalization, intensive care, and death from COVID-19 after androgen inhibition.

Results and limitations: Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20–0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52–4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders.

Conclusions: The results do not support a therapeutic effect of enzalutamide or preventive effects of bicalutamide or ADT in COVID-19. Thus, these antiandrogens should not be used for hospitalized COVID-19 patients or as prevention for COVID-19. Further research on these therapeutics in this setting are not warranted.

Patient summary: We studied whether inhibition of testosterone could diminish COVID-19 symptoms. We found no evidence of an effect in a clinical study or in epidemiological or experimental investigations. We conclude that androgen inhibition should not be used for prevention or treatment of COVID-19.

Ort, förlag, år, upplaga, sidor
Elsevier, 2022
Nyckelord
COVID-19, SARS-CoV-2, Antiandrogen, Randomized trial, Enzalutamide, Bicalutamide, Androgen deprivation therapy
Nationell ämneskategori
Cancer och onkologi Folkhälsovetenskap, global hälsa och socialmedicin Klinisk medicin Infektionsmedicin
Identifikatorer
urn:nbn:se:umu:diva-190911 (URN)10.1016/j.eururo.2021.12.013 (DOI)000809752100020 ()2-s2.0-85122412349 (Scopus ID)
Forskningsfinansiär
Knut och Alice Wallenbergs Stiftelse, 2020.0182ProstatacancerförbundetCancerfonden, 2017/478Cancerfonden, 20 1055 PjFHjärt-Lungfonden, 20200385Region Västerbotten, RV-836351Region Västerbotten, RV-939769
Tillgänglig från: 2022-01-02 Skapad: 2022-01-02 Senast uppdaterad: 2025-02-20Bibliografiskt granskad
Ljungquist, O., Lundgren, M., Iliachenko, E., Månsson, F., Böttiger, B., Landin-Olsson, M., . . . Holm, K. (2022). Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. Infectious Diseases, 54(4), 283-291
Öppna denna publikation i ny flik eller fönster >>Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases
Visa övriga...
2022 (Engelska)Ingår i: Infectious Diseases, ISSN 2374-4235, E-ISSN 2374-4243, Vol. 54, nr 4, s. 283-291Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Immunosuppressed patients are particularly vulnerable to severe infection from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), risking prolonged viremia and symptom duration. In this study we describe clinical and virological treatment outcomes in a heterogeneous group of patients with severe immunosuppression due to various causes suffering from COVID-19 infection, who were all treated with convalescent plasma (CCP) along with standard treatment.

Methods: We performed an observational, retrospective case series between May 2020 to March 2021 at three sites in Skåne, Sweden, with a population of nearly 1.4 million people. All patients hospitalized for COVID-19 who received CCP with the indication severe immunosuppression as defined by the treating physician were included in the study (n = 28).

Results: In total, 28 severely immunocompromised patients, half of which previously had been treated with rituximab, who had received in-hospital convalescent plasma treatment of COVID-19 were identified. One week after CCP treatment, 13 of 28 (46%) patients had improved clinically defined as a decrease of at least one point at the WHO-scale. Three patients had increased score points of whom two had died. For 12 patients, the WHO-scale was unchanged.

Conclusion: As one of only few studies on CCP treatment of COVID-19 in hospitalized patients with severe immunosuppression, this study adds descriptive data. The study design prohibits conclusions on safety and efficacy, and the results should be interpreted with caution. Prospective, randomized trials are needed to investigate this further.

Ort, förlag, år, upplaga, sidor
Taylor & Francis Group, 2022
Nyckelord
Antibodies, convalescent plasma, COVID-19, immunosuppression, lymphoma, pandemic, PCR, rituximab, SARS-CoV-2
Nationell ämneskategori
Infektionsmedicin
Identifikatorer
urn:nbn:se:umu:diva-190857 (URN)10.1080/23744235.2021.2013528 (DOI)000728648300001 ()34878955 (PubMedID)2-s2.0-85121359656 (Scopus ID)
Tillgänglig från: 2021-12-29 Skapad: 2021-12-29 Senast uppdaterad: 2023-04-25Bibliografiskt granskad
Welen, K., Rosendal, E., Freyhult, E., Fors Connolly, A.-M., Överby, A. K. & Josefsson, A. (2022). Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. [Letter to the editor]. European Urology, 81(5), e124-e125
Öppna denna publikation i ny flik eller fönster >>Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
Visa övriga...
2022 (Engelska)Ingår i: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 81, nr 5, s. e124-e125Artikel i tidskrift, Letter (Övrigt vetenskapligt) Published
Ort, förlag, år, upplaga, sidor
Elsevier, 2022
Nationell ämneskategori
Klinisk medicin
Identifikatorer
urn:nbn:se:umu:diva-194334 (URN)10.1016/j.eururo.2022.02.001 (DOI)000821889200009 ()35168845 (PubMedID)2-s2.0-85128336977 (Scopus ID)
Tillgänglig från: 2022-05-04 Skapad: 2022-05-04 Senast uppdaterad: 2025-02-18Bibliografiskt granskad
Welén, K., Rosendal, E., Freyhult, E., Oh, W. K., Gisslén, M., Ahlm, C., . . . Josefsson, A. (2022). Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients [Letter to the editor]. European Urology, 81(6), e143-e144
Öppna denna publikation i ny flik eller fönster >>Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients
Visa övriga...
2022 (Engelska)Ingår i: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 81, nr 6, s. e143-e144Artikel i tidskrift, Letter (Övrigt vetenskapligt) Published
Ort, förlag, år, upplaga, sidor
Elsevier, 2022
Nationell ämneskategori
Klinisk medicin
Identifikatorer
urn:nbn:se:umu:diva-196476 (URN)10.1016/j.eururo.2022.02.016 (DOI)000831850300002 ()35248411 (PubMedID)2-s2.0-85131128148 (Scopus ID)
Tillgänglig från: 2022-06-14 Skapad: 2022-06-14 Senast uppdaterad: 2025-02-18Bibliografiskt granskad
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0001-8512-0535

Sök vidare i DiVA

Visa alla publikationer